Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells $412,356.93 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 13,551 shares of the company’s stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $412,356.93. Following the sale, the chief executive officer now directly owns 418,519 shares of the company’s stock, valued at $12,735,533.17. The trade was a 3.14 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cedric Francois also recently made the following trade(s):

• On Friday, January 17th, Cedric Francois sold 6,007 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total transaction of $179,969.72.
• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total transaction of $179,288.90.

Apellis Pharmaceuticals Stock Down 2.5 %

NASDAQ APLS opened at $30.00 on Friday. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The company has a fifty day moving average of $32.08 and a two-hundred day moving average of $33.15. The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of -14.78 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s quarterly revenue was up 78.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.17) earnings per share. On average, analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Bank of America reduced their target price on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Needham & Company LLC reduced their target price on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday, January 14th. The Goldman Sachs Group lowered shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 target price for the company. in a report on Tuesday, December 17th. Finally, Mizuho reduced their target price on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a report on Thursday, October 24th. Eight research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Institutional Trading of Apellis Pharmaceuticals

A number of large investors have recently made changes to their positions in APLS. State of New Jersey Common Pension Fund D boosted its stake in shares of Apellis Pharmaceuticals by 6.6% during the second quarter. State of New Jersey Common Pension Fund D now owns 45,241 shares of the company’s stock valued at $1,735,000 after purchasing an additional 2,820 shares during the period. Envestnet Asset Management Inc. raised its holdings in shares of Apellis Pharmaceuticals by 42.2% in the second quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after acquiring an additional 39,931 shares in the last quarter. Amalgamated Bank raised its holdings in shares of Apellis Pharmaceuticals by 5.4% in the second quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock valued at $268,000 after acquiring an additional 359 shares in the last quarter. Xponance Inc. raised its holdings in shares of Apellis Pharmaceuticals by 7.6% in the second quarter. Xponance Inc. now owns 13,773 shares of the company’s stock valued at $528,000 after acquiring an additional 968 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Apellis Pharmaceuticals in the second quarter valued at about $2,350,000. 96.29% of the stock is owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).